대한뉴팜

054670KOSDAQ의약품 제조업

57.0 / 100

Reference Date: 2026-04-13

Financial Score23.5 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Rose 7.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DaeHan New Pharm operates in various sectors including specialty pharmaceuticals, non-essential pharmaceuticals (obesity & wellness injectables), and animal pharmaceuticals, focusing on chronic disease treatments and expanding into new areas such as dementia and Parkinson's. The company is diversifying its business through animal pharmaceuticals and biotech, leveraging stem cell-based anti-aging and cell therapies. Sales are structured as a multi-product, small-volume model, and the company manages foreign exchange risks through asset-liability matching strategies.

Number of Employees

393people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.83Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.76Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

11.50Industry Average 4.427.0Point

2.6x industry avg (excellent)

Debt Ratio

41.35Industry Average 11.980.0Point

3.5x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼19.0% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 12.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 7,420Won52-week high 8,38052-week low 6,380

1-month return5.0Point

1m +7.07% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-02
Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18